<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-11T19:38:48Z</responseDate>
  <request identifier="oai:figshare.com:article/34031219" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34031219</identifier>
        <datestamp>2026-09-30T10:09:15Z</datestamp>
        <setSpec>category_1</setSpec>
        <setSpec>category_4</setSpec>
        <setSpec>category_146</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_272</setSpec>
        <setSpec>category_873</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_106</setSpec>
        <setSpec>portal_63</setSpec>
        <setSpec>item_type_6</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Computer-Aided
Drug Design for Type 2 Diabetes-Related
Enzymes: SILCS-Based Fragment Mapping, Pharmacophore Modeling, and
Virtual Screening</dc:title>
          <dc:creator>Esmat Mohammadi (11974181)</dc:creator>
          <dc:creator>Justin A. Lemkul (1372401)</dc:creator>
          <dc:subject>Biophysics</dc:subject>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Space Science</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Environmental Sciences not elsewhere classified</dc:subject>
          <dc:subject>Chemical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Science Policy</dc:subject>
          <dc:subject>type 2 diabetes</dc:subject>
          <dc:subject>prioritizing candidate inhibitors</dc:subject>
          <dc:subject>maltase – glucoamylase</dc:subject>
          <dc:subject>aided drug design</dc:subject>
          <dc:subject>three enzymes associated</dc:subject>
          <dc:subject>t2d ), demonstrating</dc:subject>
          <dc:subject>strong binding efficiency</dc:subject>
          <dc:subject>ligand competitive saturation</dc:subject>
          <dc:subject>cationic probe sampling</dc:subject>
          <dc:subject>based fragment mapping</dc:subject>
          <dc:subject>based computational framework</dc:subject>
          <dc:subject>additive force fields</dc:subject>
          <dc:subject>conventional site identification</dc:subject>
          <dc:subject>probe silcs workflow</dc:subject>
          <dc:subject>improved silcs workflow</dc:subject>
          <dc:subject>refined using silcs</dc:subject>
          <dc:subject>ligand efficiency</dc:subject>
          <dc:subject>conventional workflow</dc:subject>
          <dc:subject>based silcs</dc:subject>
          <dc:subject>suppress sampling</dc:subject>
          <dc:subject>related enzymes</dc:subject>
          <dc:subject>le ),</dc:subject>
          <dc:subject>evaluated using</dc:subject>
          <dc:subject>charmm additive</dc:subject>
          <dc:subject>based clustering</dc:subject>
          <dc:subject>conventional simulations</dc:subject>
          <dc:subject>conventional mixed</dc:subject>
          <dc:subject>comprehensive silcs</dc:subject>
          <dc:subject>virtual screening</dc:subject>
          <dc:subject>suppressing neutral</dc:subject>
          <dc:subject>study develops</dc:subject>
          <dc:subject>pharmacophore models</dc:subject>
          <dc:subject>pharmacophore modeling</dc:subject>
          <dc:subject>neutral fragments</dc:subject>
          <dc:subject>improving representation</dc:subject>
          <dc:subject>hydrophobic hotspots</dc:subject>
          <dc:subject>favorable scaffolds</dc:subject>
          <dc:subject>explicitly account</dc:subject>
          <dc:subject>enhanced resolution</dc:subject>
          <dc:subject>electronic polarization</dc:subject>
          <dc:subject>chembridge libraries</dc:subject>
          <dc:subject>bonding interactions</dc:subject>
          <dc:subject>bonding features</dc:subject>
          <dc:subject>bond donor</dc:subject>
          <dc:description>Highly charged enzyme active sites present a challenge
for conventional
Site Identification by Ligand Competitive Saturation (SILCS) because
strongly interacting charged probes can suppress sampling of neutral
fragments, while additive force fields do not explicitly account for
electronic polarization. To address these limitations, we developed
a comprehensive SILCS-based computational framework and applied it
to the N-terminal and C-terminal domains of maltase–glucoamylase
and to α-amylase. Both the conventional mixed-probe SILCS workflow
and a modified neutral–charged protocol were evaluated using
the CHARMM additive and Drude polarizable force fields. FragMap convergence
analysis demonstrated reliable sampling across all systems, with the
neutral–charged protocol alleviating competitive exclusion
effects observed in conventional simulations. In highly charged catalytic
pockets, the conventional workflow was dominated by cationic probe
sampling, suppressing neutral and hydrogen-bonding features. Separation
of charged and neutral probes restored chemically diverse interaction
patterns, improving representation of hydrogen-bond donor, acceptor,
and hydrophobic hotspots. Incorporation of the Drude polarizable force
field further enhanced resolution of electrostatic and hydrogen-bonding
interactions. Energy-based SILCS-Pharmacophore models were generated
from the neutral–charged FragMaps and used for virtual screening
of the Maybridge and ChemBridge libraries. Hits were refined using
SILCS-MC, ranked by ligand grid free energy (LGFE) and ligand efficiency
(LE), and analyzed through scaffold- and fingerprint-based clustering.
Integration of energetic and structural analyses enabled identification
of favorable scaffolds and functional group patterns associated with
strong binding efficiency. Together, this study develops, evaluates,
and applies an improved SILCS workflow to three enzymes associated
with type 2 diabetes (T2D), demonstrating its utility for characterizing
highly charged active sites and prioritizing candidate inhibitors.</dc:description>
          <dc:date>2026-09-30T00:00:00Z</dc:date>
          <dc:type>Text</dc:type>
          <dc:type>Journal contribution</dc:type>
          <dc:identifier>10.1021/acs.jcim.6c01733.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/journal_contribution/Computer-Aided_Drug_Design_for_Type_2_Diabetes-Related_Enzymes_SILCS-Based_Fragment_Mapping_Pharmacophore_Modeling_and_Virtual_Screening/34031219</dc:relation>
          <dc:rights>CC BY-NC 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
